Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

11/14/24 8:37:20 AM ET

$URGN

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $URGN alert in real time by email

SC 13G/A 1 urgna1_111224.htm COWEN AND COMPANY, LLC urgna1_111224.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

UroGen Pharma Ltd.

(Name of Issuer)

Ordinary Shares

(Title of Class of Securities)

BZ7PJQ1

(CUSIP Number)

September 30, 2024

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ] Rule 13d-1(b)

[X] Rule 13d-1(c)

[ ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).

CUSIP No.: BZ7PJQ1


1	NAME OF REPORTING PERSON Cowen and Company, LLC I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) 38-3698933
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0%
12	TYPE OF REPORTING PERSON Broker Dealer

CUSIP No.: BZ7PJQ1


1	NAME OF REPORTING PERSON Cowen Financial Products LLC I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) 27-0423711
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 1,796,589
		6	SHARED VOTING POWER
		7	SOLE DISPOSITIVE POWER 1,796,589
		8	SHARED DISPOSITIVE POWER
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,796,589
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.3%
12	TYPE OF REPORTING PERSON Passive Investor

CUSIP No.: BZ7PJQ1

ITEM 1(a).	NAME OF ISSUER: UroGen Pharma Ltd.
ITEM 1(b).	ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 9 Ha'Ta'Asiya St. Ra'Anana Israel 4365007
ITEM 2(a).	NAME OF PERSON FILING: Cowen and Company, LLC Cowen Financial Products LLC
ITEM 2(b).	ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: Cowen and Company LLC: 599 Lexington Ave., New York, NY 10022 Cowen Financial Products LLC: 599 Lexington Ave., New York, NY 10022
ITEM 2(c).	CITIZENSHIP: Cowen and Company LLC: Delaware Cowen Financial Products LLC: Delaware
ITEM 2(d).	TITLE OF CLASS OF SECURITIES: Ordinary Shares
ITEM 2(e).	CUSIP NUMBER: BZ7PJQ1
ITEM 3.	IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
	(a) [ ]	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
	(b) [ ]	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
	(c) [ ]	Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
	(d) [ ]	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
	(e) [ ]	An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
	(f) [ ]	An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
	(g) [ ]	A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
	(h) [ ]	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i) [ ]	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j) [ ]	A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
	(k) [ ]	Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:

ITEM 4.	OWNERSHIP

	(a) Amount beneficially owned:
	Cowen and Company LLC: 0 Cowen Financial Products LLC: 1,796,589
	(b) Percent of class:
	Cowen and Company LLC: 0% Cowen Financial Products LLC: 4.3%
	(c) Number of shares as to which the person has:
	(i) sole power to vote or to direct the vote:
	Cowen and Company LLC: 0 Cowen Financial Products LLC: 1,796,589
	(ii) shared power to vote or to direct the vote:

	(iii) sole power to dispose or direct the disposition of:
	Cowen and Company LLC: 0 Cowen Financial Products LLC: 1,796,589
	(iv) shared power to dispose or to direct the disposition of:

ITEM 5.	OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
ITEM 6.	OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
ITEM 7.	IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
ITEM 8.	IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
ITEM 9.	NOTICE OF DISSOLUTION OF GROUP:
ITEM 10.	CERTIFICATION: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No.: BZ7PJQ1

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

November 12 2024

Cowen and Company LLC

By:

/s/ John Holmes

Name:

John Holmes

Title:

Chief Operating Officer

November 12 2024

Cowen Financial Products LLC

By:

/s/John Holmes

Name:

John Holmes

Title:

Chief Operating Officer

Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

CUSIP No.: BZ7PJQ1

CUSIP No. 001140714
SCHEDULE 13G

JOINT FILING AGREEMENT

This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the ordinary shares of UroGen Pharma Ltd. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated: November 12, 2024

Cowen and Company, LLC
By: /s/ John Holmes
Chief Operating Officer

Cowen Financial Products LLC
By: /s/ John Holmes
Chief Operating Officer

Get the next $URGN alert in real time by email

Date	Price Target	Rating	Analyst
5/22/2025		Buy → Neutral	H.C. Wainwright
4/16/2025	$23.00	Sector Outperform	Scotiabank
2/19/2025	$31.00	Buy	Ladenburg Thalmann
8/22/2024	$40.00	Buy	Guggenheim
2/8/2023	$35.00 → $10.00	Buy → Hold	Jefferies
4/27/2022	$20.00	Buy	Berenberg
1/18/2022	$50.00 → $34.00	Buy	HC Wainwright & Co.

Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

Chat with this insight

Recent Analyst Ratings for
$URGN

$URGN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by UroGen Pharma Ltd.